Details of the Drug Combinations

General Information of This Drug (ID: DM9WLN4)

Drug Name
10-hydroxycamptothecin   DM9WLN4
Synonyms
10-Hydroxycamptothecin; 19685-09-7; (S)-10-Hydroxycamptothecin; Hydroxycamptothecin; 10-hydroxycamptothecine; 10-Hydroxy camptothecin; Hydroxycamptothecine; Camptothecin, hydroxy-; 10-Hydroxy-Camptothecin; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Camptothecin, 10-hydroxy-; Camptothecine, 10-hydroxy-; UNII-9Z01632KRV; NSC 107124; HCPT; (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-Hydroxycamptothecin hydrate; NSC107124
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

770 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Meclofenamic acid DC7I819 Meclofenamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Diethylcarbamazine DCRIISS Diethylcarbamazine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + PMID28460551-Compound-2 DCOBOY6 PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + PMID28460551-Compound-2 DCFBTFV PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: K-562) [2]
10-hydroxycamptothecin + PMID28460551-Compound-2 DCIMLFW PMID28460551-Compound-2 Glioma (Cell Line: SF-539) [2]
10-hydroxycamptothecin + Plicamycin DCWHJT9 Plicamycin Astrocytoma (Cell Line: U251) [2]
10-hydroxycamptothecin + Plicamycin DCZ8IXA Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
10-hydroxycamptothecin + Plicamycin DCFIAN7 Plicamycin Glioma (Cell Line: SF-295) [2]
10-hydroxycamptothecin + Plicamycin DCJ92R4 Plicamycin Glioma (Cell Line: SF-539) [2]
10-hydroxycamptothecin + Plicamycin DCXNNX5 Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
10-hydroxycamptothecin + Triapine DC5GREU Triapine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Dexmedetomidine DCAZF4G Dexmedetomidine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Topetecan DCDSFJ0 Topetecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
10-hydroxycamptothecin + Topetecan DCOY783 Topetecan Anaplastic large cell lymphoma (Cell Line: SR) [2]
10-hydroxycamptothecin + Topetecan DCXW2S0 Topetecan Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
10-hydroxycamptothecin + Topetecan DCRP3VF Topetecan Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
10-hydroxycamptothecin + Topetecan DCU4BT1 Topetecan Glioma (Cell Line: SF-539) [2]
10-hydroxycamptothecin + Topetecan DCW0QG2 Topetecan Papillary renal cell carcinoma (Cell Line: ACHN) [2]
10-hydroxycamptothecin + Topetecan DC6GYJT Topetecan Renal cell carcinoma (Cell Line: SN12C) [2]
10-hydroxycamptothecin + Terameprocol DCBTSP9 Terameprocol Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + SCH 727965 DCXUHYR SCH 727965 Glioma (Cell Line: SF-295) [2]
10-hydroxycamptothecin + Emetine DCCJUF3 Emetine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Metformin DCO9EQM Metformin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Phensuximide DCQ5M3D Phensuximide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Fibrates DCZLSQ4 Fibrates Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Fluspirilene DCNA89B Fluspirilene Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Mitomycin DCTLWDD Mitomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
10-hydroxycamptothecin + Mitomycin DCHT0WC Mitomycin Chronic myelogenous leukemia (Cell Line: K-562) [2]
10-hydroxycamptothecin + Mitomycin DC9GTNX Mitomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
10-hydroxycamptothecin + Mitomycin DC20EHL Mitomycin Glioma (Cell Line: SF-295) [2]
10-hydroxycamptothecin + Mitomycin DCUPKVK Mitomycin Glioma (Cell Line: SF-539) [2]
10-hydroxycamptothecin + Mitomycin DCN7A9H Mitomycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
10-hydroxycamptothecin + GINKGOLIDE A DCAYIQX GINKGOLIDE A Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Idarubicin DCV5BK9 Idarubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Bleomycin DCGVT54 Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
10-hydroxycamptothecin + Bleomycin DCDD3MS Bleomycin Astrocytoma (Cell Line: U251) [2]
10-hydroxycamptothecin + Valrubicin DCGUQTH Valrubicin Anaplastic large cell lymphoma (Cell Line: SR) [2]
10-hydroxycamptothecin + Valrubicin DCAOWUL Valrubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
10-hydroxycamptothecin + Valrubicin DC3PF9Q Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [2]
10-hydroxycamptothecin + Valrubicin DCIK4TW Valrubicin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
10-hydroxycamptothecin + Oxyphenbutazone DC2BALQ Oxyphenbutazone Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Leflunomide DCR279X Leflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Cisplatin DCACZBO Cisplatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
10-hydroxycamptothecin + Cisplatin DCVUD6J Cisplatin Anaplastic large cell lymphoma (Cell Line: SR) [2]
10-hydroxycamptothecin + Cisplatin DC6L21O Cisplatin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
10-hydroxycamptothecin + Cisplatin DCHKH7A Cisplatin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
10-hydroxycamptothecin + Cisplatin DC2S90X Cisplatin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
10-hydroxycamptothecin + Chlorambucil DC9M2Y5 Chlorambucil Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
10-hydroxycamptothecin + Chlorambucil DCX9JDL Chlorambucil Astrocytoma (Cell Line: SNB-19) [2]
10-hydroxycamptothecin + Chlorambucil DCQ9JNR Chlorambucil Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
10-hydroxycamptothecin + Chlorambucil DCRCD4C Chlorambucil Glioma (Cell Line: SF-539) [2]
10-hydroxycamptothecin + Sorafenib DCVTWGQ Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
10-hydroxycamptothecin + Mercaptopurine DCLIU04 Mercaptopurine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
10-hydroxycamptothecin + Mercaptopurine DCY012P Mercaptopurine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
10-hydroxycamptothecin + Mepacrine DC9JZVC Mepacrine Glioma (Cell Line: SF-539) [2]
10-hydroxycamptothecin + Doxorubicin DCL4NCM Doxorubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Sumatriptan DCK50XM Sumatriptan Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Olmesartan medoxomil DCJJYBS Olmesartan medoxomil Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Vorinostat DC4XU37 Vorinostat Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Aminolevulinic Acid Hydrochloride DCV73TI Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
10-hydroxycamptothecin + Azatadine DC3SLHS Azatadine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
10-hydroxycamptothecin + Fulvestrant DCK7XSS Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [3]
10-hydroxycamptothecin + PMID28460551-Compound-2 DCXHZOY PMID28460551-Compound-2 Colon carcinoma (Cell Line: KM12) [3]
10-hydroxycamptothecin + Methotrexate DC30Z5K Methotrexate Invasive ductal carcinoma (Cell Line: T-47D) [3]
10-hydroxycamptothecin + SCH-900776 DCHRE1S SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
10-hydroxycamptothecin + SCH-900776 DC8NQQO SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
10-hydroxycamptothecin + Plicamycin DC6WNSL Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
10-hydroxycamptothecin + Topetecan DCC8BXS Topetecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
10-hydroxycamptothecin + Bendamustine hydrochloride DCNYJIL Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: BT-549) [3]
10-hydroxycamptothecin + Mitomycin DCX5S03 Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
10-hydroxycamptothecin + Mitomycin DCZR08E Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
10-hydroxycamptothecin + Ridaforolimus DCC7TWY Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
10-hydroxycamptothecin + Bortezomib DCRK54K Bortezomib Invasive ductal carcinoma (Cell Line: T-47D) [3]
10-hydroxycamptothecin + Cisplatin DC7OF5M Cisplatin Colon adenocarcinoma (Cell Line: COLO 205) [3]
10-hydroxycamptothecin + Chlorambucil DCYK5KK Chlorambucil Colon adenocarcinoma (Cell Line: COLO 205) [3]
10-hydroxycamptothecin + Sorafenib DCX353Y Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
10-hydroxycamptothecin + Sorafenib DC554K3 Sorafenib Breast carcinoma (Cell Line: ZR751) [3]
10-hydroxycamptothecin + Sorafenib DCMUCGC Sorafenib Breast carcinoma (Cell Line: KPL1) [3]
10-hydroxycamptothecin + Sorafenib DCY4LJ6 Sorafenib Breast carcinoma (Cell Line: OCUBM) [3]
10-hydroxycamptothecin + Sorafenib DC4D8JA Sorafenib Carcinoma (Cell Line: OV90) [3]
10-hydroxycamptothecin + Sorafenib DCI5KPR Sorafenib Colon carcinoma (Cell Line: RKO) [3]
10-hydroxycamptothecin + Sorafenib DCL5XRI Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
10-hydroxycamptothecin + Vinflunine DC1MZTG Vinflunine Colon carcinoma (Cell Line: KM12) [3]
10-hydroxycamptothecin + FORMESTANE DCOQX8S FORMESTANE Carcinoma (Cell Line: MCF7) [3]
10-hydroxycamptothecin + Ombrabulin DC1FPAC Ombrabulin Hodgkin lymphoma (Cell Line: L-1236) [4]
10-hydroxycamptothecin + Ixabepilone DCJP8K0 Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
10-hydroxycamptothecin + PMID28460551-Compound-2 DCIEEUC PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
10-hydroxycamptothecin + Panobinostat DCTTZP4 Panobinostat Hodgkin lymphoma (Cell Line: L-1236) [4]
10-hydroxycamptothecin + Arsenic trioxide DCALZTR Arsenic trioxide Melanoma (Cell Line: SK-MEL-2) [4]
10-hydroxycamptothecin + SCH-900776 DCSTISN SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [4]
10-hydroxycamptothecin + SCH-900776 DCNHJHZ SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [4]
10-hydroxycamptothecin + SCH-900776 DCQGMIV SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [4]
10-hydroxycamptothecin + SCH-900776 DC91IWK SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [4]
10-hydroxycamptothecin + SCH-900776 DCJMOTP SCH-900776 Adenocarcinoma (Cell Line: HT29) [4]
10-hydroxycamptothecin + SCH-900776 DCF6ISV SCH-900776 Amelanotic melanoma (Cell Line: A2058) [4]
10-hydroxycamptothecin + SCH-900776 DCKZVU9 SCH-900776 Germ cell tumour (Cell Line: PA1) [4]
10-hydroxycamptothecin + SCH-900776 DCLL2UG SCH-900776 Malignant melanoma (Cell Line: A375) [4]
10-hydroxycamptothecin + SCH-900776 DCY86O0 SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [4]
10-hydroxycamptothecin + SCH-900776 DCN4BHW SCH-900776 Mesothelioma (Cell Line: MSTO) [4]
10-hydroxycamptothecin + SCH-900776 DCUDNPU SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
10-hydroxycamptothecin + SCH-900776 DCF1JOZ SCH-900776 Prostate carcinoma (Cell Line: VCAP) [4]
10-hydroxycamptothecin + Plicamycin DCQKVOF Plicamycin Adenocarcinoma (Cell Line: DU-145) [4]
10-hydroxycamptothecin + Plicamycin DCFCX88 Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
10-hydroxycamptothecin + Triapine DC8HUWL Triapine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
10-hydroxycamptothecin + Topetecan DCLAW1L Topetecan Adenocarcinoma (Cell Line: DU-145) [4]
10-hydroxycamptothecin + Topetecan DCQFK31 Topetecan Adenocarcinoma (Cell Line: A549) [4]
10-hydroxycamptothecin + Topetecan DCAQZW2 Topetecan Adenocarcinoma (Cell Line: HCT116) [4]
10-hydroxycamptothecin + Topetecan DC7E9BG Topetecan Large cell lung carcinoma (Cell Line: NCI-H460) [4]
10-hydroxycamptothecin + Topetecan DCNMWLQ Topetecan Lung adenocarcinoma (Cell Line: HOP-62) [4]
10-hydroxycamptothecin + Pralatrexate DC100RS Pralatrexate Adenocarcinoma (Cell Line: OVCAR3) [4]
10-hydroxycamptothecin + SCH 727965 DCCE56W SCH 727965 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
10-hydroxycamptothecin + Bendamustine hydrochloride DCQI67T Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT116) [4]
10-hydroxycamptothecin + Bendamustine hydrochloride DC8EB5I Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [4]
10-hydroxycamptothecin + Bendamustine hydrochloride DC8O1K0 Bendamustine hydrochloride Adenocarcinoma (Cell Line: SW-620) [4]
10-hydroxycamptothecin + Bendamustine hydrochloride DCDF2GH Bendamustine hydrochloride Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
10-hydroxycamptothecin + Mitomycin DCNMBK8 Mitomycin Adenocarcinoma (Cell Line: DU-145) [4]
10-hydroxycamptothecin + Mitomycin DCTN9C5 Mitomycin Adenocarcinoma (Cell Line: A549) [4]
10-hydroxycamptothecin + Mitomycin DCSLR0M Mitomycin Adenocarcinoma (Cell Line: NCIH23) [4]
10-hydroxycamptothecin + Mitomycin DCETOPZ Mitomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
10-hydroxycamptothecin + Mitomycin DC43V2K Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
10-hydroxycamptothecin + Mitomycin DC0Q86I Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
10-hydroxycamptothecin + Altretamine DCQYCPU Altretamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
10-hydroxycamptothecin + Ridaforolimus DC1RUS2 Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [4]
10-hydroxycamptothecin + Ridaforolimus DCT9ZFR Ridaforolimus Adenocarcinoma (Cell Line: NCIH520) [4]
10-hydroxycamptothecin + Ridaforolimus DC0L68I Ridaforolimus Adenocarcinoma (Cell Line: HT29) [4]
10-hydroxycamptothecin + Ridaforolimus DC4X7ZW Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [4]
10-hydroxycamptothecin + Ridaforolimus DCJ4JQG Ridaforolimus Mesothelioma (Cell Line: MSTO) [4]
10-hydroxycamptothecin + Ridaforolimus DCZ1UER Ridaforolimus Non small cell carcinoma (Cell Line: SKMES1) [4]
10-hydroxycamptothecin + Ridaforolimus DCYP0SO Ridaforolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
10-hydroxycamptothecin + Ridaforolimus DCKTR1W Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [4]
10-hydroxycamptothecin + TEM DC763Y7 TEM Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
10-hydroxycamptothecin + Bortezomib DCFK1RX Bortezomib Adenocarcinoma (Cell Line: OVCAR3) [4]
10-hydroxycamptothecin + Bortezomib DCE3AXA Bortezomib Adenocarcinoma (Cell Line: A549) [4]
10-hydroxycamptothecin + Bortezomib DC9SBLB Bortezomib Adenocarcinoma (Cell Line: HCT116) [4]
10-hydroxycamptothecin + Bortezomib DCS2K45 Bortezomib Amelanotic melanoma (Cell Line: M14) [4]
10-hydroxycamptothecin + Bortezomib DCS9XJQ Bortezomib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
10-hydroxycamptothecin + Bortezomib DCFAV0W Bortezomib Hodgkin lymphoma (Cell Line: L-1236) [4]
10-hydroxycamptothecin + Bortezomib DCASIEE Bortezomib Malignant melanoma (Cell Line: UACC62) [4]
10-hydroxycamptothecin + Valrubicin DC9F6QD Valrubicin Adenocarcinoma (Cell Line: NCIH23) [4]
10-hydroxycamptothecin + Valrubicin DC3BDSK Valrubicin Adenocarcinoma (Cell Line: HCT-15) [4]
10-hydroxycamptothecin + Valrubicin DCBLUSP Valrubicin Amelanotic melanoma (Cell Line: M14) [4]
10-hydroxycamptothecin + Valrubicin DCYD840 Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
10-hydroxycamptothecin + Valrubicin DCVLE7W Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [4]
10-hydroxycamptothecin + Valrubicin DCKJTRS Valrubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
10-hydroxycamptothecin + Valrubicin DC8R9Q2 Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
10-hydroxycamptothecin + Cisplatin DCXC12P Cisplatin Malignant melanoma (Cell Line: LOX IMVI) [4]
10-hydroxycamptothecin + Cisplatin DC4I50L Cisplatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
10-hydroxycamptothecin + Sorafenib DC3Z4YC Sorafenib Adenocarcinoma (Cell Line: CAOV3) [4]
10-hydroxycamptothecin + Sorafenib DCZ9CKG Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
10-hydroxycamptothecin + Sorafenib DCOXVUH Sorafenib Adenocarcinoma (Cell Line: A427) [4]
10-hydroxycamptothecin + Sorafenib DCDFQQE Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [4]
10-hydroxycamptothecin + Sorafenib DCJMX90 Sorafenib Adenocarcinoma (Cell Line: NCIH2122) [4]
10-hydroxycamptothecin + Sorafenib DCRU7O5 Sorafenib Adenocarcinoma (Cell Line: NCIH23) [4]
10-hydroxycamptothecin + Sorafenib DCB73FG Sorafenib Adenocarcinoma (Cell Line: NCIH520) [4]
10-hydroxycamptothecin + Sorafenib DCIEL8S Sorafenib Adenocarcinoma (Cell Line: DLD1) [4]
10-hydroxycamptothecin + Sorafenib DC88CP6 Sorafenib Adenocarcinoma (Cell Line: SW-620) [4]
10-hydroxycamptothecin + Sorafenib DCJY8DY Sorafenib Amelanotic melanoma (Cell Line: A2058) [4]
10-hydroxycamptothecin + Sorafenib DCAPECE Sorafenib Germ cell tumour (Cell Line: PA1) [4]
10-hydroxycamptothecin + Sorafenib DCI6HDO Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
10-hydroxycamptothecin + Sorafenib DCX03FG Sorafenib Malignant melanoma (Cell Line: A375) [4]
10-hydroxycamptothecin + Sorafenib DCDDAOX Sorafenib Malignant melanoma (Cell Line: HT144) [4]
10-hydroxycamptothecin + Sorafenib DCI7O5V Sorafenib Malignant melanoma (Cell Line: SKMEL30) [4]
10-hydroxycamptothecin + Sorafenib DCQBGBP Sorafenib Malignant melanoma (Cell Line: UACC62) [4]
10-hydroxycamptothecin + Sorafenib DCBC6BN Sorafenib Mesothelioma (Cell Line: MSTO) [4]
10-hydroxycamptothecin + Sorafenib DCXZ5IX Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [4]
10-hydroxycamptothecin + Sorafenib DCMM51T Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
10-hydroxycamptothecin + Sorafenib DCMW3YK Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
10-hydroxycamptothecin + Sorafenib DCM3YKH Sorafenib Prostate carcinoma (Cell Line: VCAP) [4]
10-hydroxycamptothecin + ER819762 DC6XWVV ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
10-hydroxycamptothecin + Azacitidine DCG46ZI Azacitidine Adenocarcinoma (Cell Line: HCC-2998) [4]
10-hydroxycamptothecin + Azacitidine DCPZYHB Azacitidine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
10-hydroxycamptothecin + Azacitidine DCAVVER Azacitidine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
10-hydroxycamptothecin + Vinflunine DC2RJZ5 Vinflunine Lung adenocarcinoma (Cell Line: NCI-H522) [4]
10-hydroxycamptothecin + Mercaptopurine DCUQKYP Mercaptopurine Adenocarcinoma (Cell Line: HCT-15) [4]
10-hydroxycamptothecin + Mercaptopurine DC2OH6K Mercaptopurine Melanoma (Cell Line: UACC-257) [4]
10-hydroxycamptothecin + Mepacrine DCY3FAI Mepacrine Adenocarcinoma (Cell Line: DU-145) [4]
10-hydroxycamptothecin + FORMESTANE DCM6PTX FORMESTANE Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
10-hydroxycamptothecin + Aminolevulinic Acid Hydrochloride DCBA02B Aminolevulinic Acid Hydrochloride Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
10-hydroxycamptothecin + BGT226 DCPUOBH BGT226 Hodgkin lymphoma (Cell Line: L-1236) [4]
10-hydroxycamptothecin + Busulfan DCQAWUZ Busulfan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
ABIRATERONE + 10-hydroxycamptothecin DC148N2 ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [2]
ABIRATERONE + 10-hydroxycamptothecin DCYUAME ABIRATERONE Plasma cell myeloma (Cell Line: RPMI-8226) [2]
ABIRATERONE + 10-hydroxycamptothecin DCTCAUC ABIRATERONE Carcinoma (Cell Line: RXF 393) [3]
ABIRATERONE + 10-hydroxycamptothecin DCEAU26 ABIRATERONE Adenocarcinoma (Cell Line: OVCAR3) [4]
ABIRATERONE + 10-hydroxycamptothecin DCDE2A9 ABIRATERONE Adenocarcinoma (Cell Line: SW-620) [4]
ABIRATERONE + 10-hydroxycamptothecin DCLHYDX ABIRATERONE Adenocarcinoma (Cell Line: HCC-2998) [4]
ABIRATERONE + 10-hydroxycamptothecin DCG530I ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
ABIRATERONE + 10-hydroxycamptothecin DCZ6N6G ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
ABIRATERONE + 10-hydroxycamptothecin DCHELE6 ABIRATERONE Large cell lung carcinoma (Cell Line: NCI-H460) [4]
ABIRATERONE + 10-hydroxycamptothecin DCD2EUY ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
ABIRATERONE + 10-hydroxycamptothecin DCO5DU4 ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [4]
Amonafide + 10-hydroxycamptothecin DC1BP5X Amonafide Adenocarcinoma (Cell Line: OVCAR3) [2]
Amonafide + 10-hydroxycamptothecin DCCUDXF Amonafide Adenocarcinoma (Cell Line: HT29) [2]
Amonafide + 10-hydroxycamptothecin DCJ4YOB Amonafide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Anastrozole + 10-hydroxycamptothecin DCRFXLO Anastrozole Adenocarcinoma (Cell Line: HCT116) [2]
Anastrozole + 10-hydroxycamptothecin DC1WDME Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Anastrozole + 10-hydroxycamptothecin DCUVWOU Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Anastrozole + 10-hydroxycamptothecin DCLTBHM Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Arfolitixorin + 10-hydroxycamptothecin DC75YUX Arfolitixorin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Arfolitixorin + 10-hydroxycamptothecin DC7LKBI Arfolitixorin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Arfolitixorin + 10-hydroxycamptothecin DCSSQ3V Arfolitixorin Glioma (Cell Line: SF-295) [2]
BIO-300 + 10-hydroxycamptothecin DCJTPMR BIO-300 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Bleomycin + 10-hydroxycamptothecin DC3KVPI Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Bleomycin + 10-hydroxycamptothecin DCFHTCU Bleomycin Glioma (Cell Line: SF-539) [2]
Bleomycin + 10-hydroxycamptothecin DCWQPEP Bleomycin Adenocarcinoma (Cell Line: A549) [4]
Bortezomib + 10-hydroxycamptothecin DCYXJ5R Bortezomib Adenocarcinoma (Cell Line: CAOV3) [2]
Bortezomib + 10-hydroxycamptothecin DC7OLQ0 Bortezomib Adenocarcinoma (Cell Line: A427) [2]
Bortezomib + 10-hydroxycamptothecin DCKSUGC Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [2]
Bortezomib + 10-hydroxycamptothecin DCRGVJO Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [2]
Bortezomib + 10-hydroxycamptothecin DCPZVWM Bortezomib Adenocarcinoma (Cell Line: HT29) [2]
Bortezomib + 10-hydroxycamptothecin DC3BT5J Bortezomib Adenocarcinoma (Cell Line: SW-620) [2]
Bortezomib + 10-hydroxycamptothecin DCYH91F Bortezomib Amelanotic melanoma (Cell Line: A2058) [2]
Bortezomib + 10-hydroxycamptothecin DCRON4K Bortezomib Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Bortezomib + 10-hydroxycamptothecin DC6JFIA Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Bortezomib + 10-hydroxycamptothecin DCI759X Bortezomib Germ cell tumour (Cell Line: PA1) [2]
Bortezomib + 10-hydroxycamptothecin DC7VHPJ Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Bortezomib + 10-hydroxycamptothecin DCCG7BS Bortezomib Malignant melanoma (Cell Line: A375) [2]
Bortezomib + 10-hydroxycamptothecin DC6QTWC Bortezomib Malignant melanoma (Cell Line: SKMEL30) [2]
Bortezomib + 10-hydroxycamptothecin DCY0S5J Bortezomib Malignant melanoma (Cell Line: UACC62) [2]
Bortezomib + 10-hydroxycamptothecin DCNU0LJ Bortezomib Mesothelioma (Cell Line: MSTO) [2]
Bortezomib + 10-hydroxycamptothecin DCO63PK Bortezomib Non small cell carcinoma (Cell Line: SKMES1) [2]
Bortezomib + 10-hydroxycamptothecin DCYE72I Bortezomib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Bortezomib + 10-hydroxycamptothecin DCT4N3E Bortezomib Prostate carcinoma (Cell Line: LNCAP) [2]
Bortezomib + 10-hydroxycamptothecin DC2CW60 Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Bortezomib + 10-hydroxycamptothecin DC8H1UD Bortezomib Breast carcinoma (Cell Line: ZR751) [3]
Bortezomib + 10-hydroxycamptothecin DCVHMJ7 Bortezomib Breast carcinoma (Cell Line: KPL1) [3]
Bortezomib + 10-hydroxycamptothecin DCFF5AO Bortezomib Breast carcinoma (Cell Line: OCUBM) [3]
Bortezomib + 10-hydroxycamptothecin DC3CWEW Bortezomib Carcinoma (Cell Line: MDAMB436) [3]
Bortezomib + 10-hydroxycamptothecin DC5RIIZ Bortezomib Colon carcinoma (Cell Line: RKO) [3]
Bortezomib + 10-hydroxycamptothecin DC97LID Bortezomib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Bortezomib + 10-hydroxycamptothecin DC8BQL9 Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [3]
Brincidofovir + 10-hydroxycamptothecin DCL2W6C Brincidofovir Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Cabazitaxel + 10-hydroxycamptothecin DC5XS5B Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [2]
Cabazitaxel + 10-hydroxycamptothecin DCTAA5X Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [2]
Cabazitaxel + 10-hydroxycamptothecin DCW15IV Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [2]
Cabazitaxel + 10-hydroxycamptothecin DCKG46N Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Cabazitaxel + 10-hydroxycamptothecin DC0C947 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: A498) [2]
Cabazitaxel + 10-hydroxycamptothecin DCKRGA9 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Cabazitaxel + 10-hydroxycamptothecin DC30GP6 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Cabazitaxel + 10-hydroxycamptothecin DCDTFRE Cabazitaxel Glioma (Cell Line: SF-295) [2]
Cabazitaxel + 10-hydroxycamptothecin DCLZGGK Cabazitaxel Glioma (Cell Line: SF-268) [2]
Cabazitaxel + 10-hydroxycamptothecin DCQDJGG Cabazitaxel Glioma (Cell Line: SF-539) [2]
Cabazitaxel + 10-hydroxycamptothecin DCXVXTY Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Cabazitaxel + 10-hydroxycamptothecin DC9WA37 Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [2]
Cabazitaxel + 10-hydroxycamptothecin DCYQGNQ Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [2]
Cabazitaxel + 10-hydroxycamptothecin DCWLN41 Cabazitaxel Malignant melanoma (Cell Line: LOX IMVI) [2]
Cabazitaxel + 10-hydroxycamptothecin DC9OV79 Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [2]
Cabazitaxel + 10-hydroxycamptothecin DCKWBQO Cabazitaxel Carcinoma (Cell Line: RXF 393) [3]
Cerivastatin + 10-hydroxycamptothecin DC080SX Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Chlormezanone + 10-hydroxycamptothecin DC9OMGB Chlormezanone Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Chlorzoxazone + 10-hydroxycamptothecin DCPBGRJ Chlorzoxazone Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Crizotinib + 10-hydroxycamptothecin DCXPA25 Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + 10-hydroxycamptothecin DCB4EG6 Crizotinib Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + 10-hydroxycamptothecin DCB5W32 Crizotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + 10-hydroxycamptothecin DCIZJHQ Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + 10-hydroxycamptothecin DCIJ8CM Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + 10-hydroxycamptothecin DCITZAW Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + 10-hydroxycamptothecin DCFVWMS Crizotinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + 10-hydroxycamptothecin DCIRK7X Crizotinib Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + 10-hydroxycamptothecin DCTT6ZN Crizotinib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Dacarbazine + 10-hydroxycamptothecin DCWZIZX Dacarbazine Adenocarcinoma (Cell Line: OVCAR3) [2]
Dacarbazine + 10-hydroxycamptothecin DCOWB5D Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Dacarbazine + 10-hydroxycamptothecin DCO6WKI Dacarbazine Glioma (Cell Line: SF-295) [2]
Dacarbazine + 10-hydroxycamptothecin DCWSBM9 Dacarbazine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Dactinomycin + 10-hydroxycamptothecin DCNH3XX Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Dactinomycin + 10-hydroxycamptothecin DC7HY5F Dactinomycin Astrocytoma (Cell Line: U251) [4]
Dactinomycin + 10-hydroxycamptothecin DCJUYVI Dactinomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Dasatinib + 10-hydroxycamptothecin DC2RPVM Dasatinib Adenocarcinoma (Cell Line: CAOV3) [2]
Dasatinib + 10-hydroxycamptothecin DCK7RWP Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [2]
Dasatinib + 10-hydroxycamptothecin DCRDUDN Dasatinib Adenocarcinoma (Cell Line: A427) [2]
Dasatinib + 10-hydroxycamptothecin DCLLG0W Dasatinib Adenocarcinoma (Cell Line: NCIH1650) [2]
Dasatinib + 10-hydroxycamptothecin DCB2666 Dasatinib Adenocarcinoma (Cell Line: NCIH23) [2]
Dasatinib + 10-hydroxycamptothecin DCH8UPR Dasatinib Adenocarcinoma (Cell Line: NCIH520) [2]
Dasatinib + 10-hydroxycamptothecin DCLRNAG Dasatinib Adenocarcinoma (Cell Line: DLD1) [2]
Dasatinib + 10-hydroxycamptothecin DCKG2HH Dasatinib Adenocarcinoma (Cell Line: HT29) [2]
Dasatinib + 10-hydroxycamptothecin DCGR1TG Dasatinib Amelanotic melanoma (Cell Line: A2058) [2]
Dasatinib + 10-hydroxycamptothecin DCBGU6J Dasatinib Germ cell tumour (Cell Line: PA1) [2]
Dasatinib + 10-hydroxycamptothecin DCNG4C6 Dasatinib Malignant melanoma (Cell Line: A375) [2]
Dasatinib + 10-hydroxycamptothecin DC06N4Z Dasatinib Malignant melanoma (Cell Line: RPMI7951) [2]
Dasatinib + 10-hydroxycamptothecin DCV91GT Dasatinib Malignant melanoma (Cell Line: UACC62) [2]
Dasatinib + 10-hydroxycamptothecin DCE4WD5 Dasatinib Mesothelioma (Cell Line: MSTO) [2]
Dasatinib + 10-hydroxycamptothecin DCTC73M Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Dasatinib + 10-hydroxycamptothecin DCE96H4 Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Dasatinib + 10-hydroxycamptothecin DCXB44A Dasatinib Prostate carcinoma (Cell Line: VCAP) [2]
Dasatinib + 10-hydroxycamptothecin DC8AJ6K Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Dasatinib + 10-hydroxycamptothecin DCTLIE8 Dasatinib Breast carcinoma (Cell Line: OCUBM) [3]
Dasatinib + 10-hydroxycamptothecin DC9D8RI Dasatinib Colon adenocarcinoma (Cell Line: LOVO) [3]
Dasatinib + 10-hydroxycamptothecin DCTA2SC Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Dasatinib + 10-hydroxycamptothecin DC1RN5U Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [3]
Dexrazoxane + 10-hydroxycamptothecin DCTC27D Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Dexrazoxane + 10-hydroxycamptothecin DC2HVG4 Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [2]
Dexrazoxane + 10-hydroxycamptothecin DC28H93 Dexrazoxane Adenocarcinoma (Cell Line: DU-145) [4]
Dexrazoxane + 10-hydroxycamptothecin DCDMOSE Dexrazoxane Adenocarcinoma (Cell Line: HT29) [4]
DFN-15 + 10-hydroxycamptothecin DC7QM5P DFN-15 Glioma (Cell Line: SF-295) [2]
DFN-15 + 10-hydroxycamptothecin DCRWZ5B DFN-15 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Digitoxin + 10-hydroxycamptothecin DCOR1GR Digitoxin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Docetaxel + 10-hydroxycamptothecin DCR358L Docetaxel Astrocytoma (Cell Line: U251) [2]
Docetaxel + 10-hydroxycamptothecin DCYHD90 Docetaxel Astrocytoma (Cell Line: SNB-19) [2]
Docetaxel + 10-hydroxycamptothecin DC0VIBR Docetaxel Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Doxorubicin + 10-hydroxycamptothecin DCCHTXX Doxorubicin Hodgkin lymphoma (Cell Line: L-1236) [2]
Eflornithine + 10-hydroxycamptothecin DCA5326 Eflornithine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Epirubicin + 10-hydroxycamptothecin DCUEVC5 Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + 10-hydroxycamptothecin DCRNGYH Epirubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Erlotinib + 10-hydroxycamptothecin DC1X7QO Erlotinib Adenocarcinoma (Cell Line: CAOV3) [2]
Erlotinib + 10-hydroxycamptothecin DCBVTYP Erlotinib Adenocarcinoma (Cell Line: A427) [2]
Erlotinib + 10-hydroxycamptothecin DCG592S Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [2]
Erlotinib + 10-hydroxycamptothecin DCTWYSV Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [2]
Erlotinib + 10-hydroxycamptothecin DCOGCDV Erlotinib Adenocarcinoma (Cell Line: NCIH23) [2]
Erlotinib + 10-hydroxycamptothecin DCMDS39 Erlotinib Adenocarcinoma (Cell Line: NCIH520) [2]
Erlotinib + 10-hydroxycamptothecin DC6HO3V Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [2]
Erlotinib + 10-hydroxycamptothecin DCXKO6O Erlotinib Adenocarcinoma (Cell Line: DLD1) [2]
Erlotinib + 10-hydroxycamptothecin DC0IQDD Erlotinib Adenocarcinoma (Cell Line: HT29) [2]
Erlotinib + 10-hydroxycamptothecin DCDDHWD Erlotinib Adenocarcinoma (Cell Line: SW-620) [2]
Erlotinib + 10-hydroxycamptothecin DCFG7PH Erlotinib Amelanotic melanoma (Cell Line: A2058) [2]
Erlotinib + 10-hydroxycamptothecin DCHSL6N Erlotinib Germ cell tumour (Cell Line: PA1) [2]
Erlotinib + 10-hydroxycamptothecin DCZZXKZ Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Erlotinib + 10-hydroxycamptothecin DCEFY8Y Erlotinib Malignant melanoma (Cell Line: A375) [2]
Erlotinib + 10-hydroxycamptothecin DC3FKYU Erlotinib Malignant melanoma (Cell Line: RPMI7951) [2]
Erlotinib + 10-hydroxycamptothecin DCRJZMI Erlotinib Malignant melanoma (Cell Line: SKMEL30) [2]
Erlotinib + 10-hydroxycamptothecin DCYYXS7 Erlotinib Malignant melanoma (Cell Line: UACC62) [2]
Erlotinib + 10-hydroxycamptothecin DCK3F2V Erlotinib Mesothelioma (Cell Line: MSTO) [2]
Erlotinib + 10-hydroxycamptothecin DCWQNS1 Erlotinib Non small cell carcinoma (Cell Line: SKMES1) [2]
Erlotinib + 10-hydroxycamptothecin DCSQ842 Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Erlotinib + 10-hydroxycamptothecin DCXU8TY Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Erlotinib + 10-hydroxycamptothecin DCS0I32 Erlotinib Prostate carcinoma (Cell Line: VCAP) [2]
Erlotinib + 10-hydroxycamptothecin DCF5V77 Erlotinib Breast carcinoma (Cell Line: ZR751) [3]
Erlotinib + 10-hydroxycamptothecin DCNI3YD Erlotinib Breast carcinoma (Cell Line: KPL1) [3]
Erlotinib + 10-hydroxycamptothecin DCDSBTQ Erlotinib Breast carcinoma (Cell Line: OCUBM) [3]
Erlotinib + 10-hydroxycamptothecin DCM9BX0 Erlotinib Carcinoma (Cell Line: EFM192B) [3]
Erlotinib + 10-hydroxycamptothecin DCBXWUE Erlotinib Carcinoma (Cell Line: MDAMB436) [3]
Erlotinib + 10-hydroxycamptothecin DCZZMOX Erlotinib Colon adenocarcinoma (Cell Line: LOVO) [3]
Erlotinib + 10-hydroxycamptothecin DCPWB4E Erlotinib Colon carcinoma (Cell Line: RKO) [3]
Erlotinib + 10-hydroxycamptothecin DC818JB Erlotinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Erlotinib + 10-hydroxycamptothecin DCTRE1E Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [3]
Estramustine + 10-hydroxycamptothecin DC36IO0 Estramustine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Estramustine + 10-hydroxycamptothecin DCZVNDY Estramustine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Estramustine + 10-hydroxycamptothecin DCBH8D7 Estramustine Adenocarcinoma (Cell Line: SW-620) [4]
Fludarabine + 10-hydroxycamptothecin DCC314L Fludarabine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Fludarabine + 10-hydroxycamptothecin DCV55DR Fludarabine Amelanotic melanoma (Cell Line: M14) [4]
Fludarabine + 10-hydroxycamptothecin DCE13ZU Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Fludarabine + 10-hydroxycamptothecin DC095DA Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Fluorouracil + 10-hydroxycamptothecin DCJ1G8L Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Fluorouracil + 10-hydroxycamptothecin DC2YD4T Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Fluorouracil + 10-hydroxycamptothecin DC8LLV4 Fluorouracil Breast carcinoma (Cell Line: KPL1) [3]
Fluorouracil + 10-hydroxycamptothecin DCXKB9R Fluorouracil Breast carcinoma (Cell Line: OCUBM) [3]
Fluorouracil + 10-hydroxycamptothecin DCI46IY Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [3]
Fluorouracil + 10-hydroxycamptothecin DC9UZUW Fluorouracil Colon carcinoma (Cell Line: RKO) [3]
Fluorouracil + 10-hydroxycamptothecin DCDYB8W Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [3]
Fluorouracil + 10-hydroxycamptothecin DCPD1NU Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [4]
Fluorouracil + 10-hydroxycamptothecin DC3CVP4 Fluorouracil Adenocarcinoma (Cell Line: A427) [4]
Fluorouracil + 10-hydroxycamptothecin DCGO3UW Fluorouracil Adenocarcinoma (Cell Line: NCIH2122) [4]
Fluorouracil + 10-hydroxycamptothecin DC6CRUS Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [4]
Fluorouracil + 10-hydroxycamptothecin DCYRJ4S Fluorouracil Adenocarcinoma (Cell Line: HCT116) [4]
Fluorouracil + 10-hydroxycamptothecin DC956OX Fluorouracil Adenocarcinoma (Cell Line: HT29) [4]
Fluorouracil + 10-hydroxycamptothecin DCBL645 Fluorouracil Germ cell tumour (Cell Line: PA1) [4]
Fluorouracil + 10-hydroxycamptothecin DCRGG7P Fluorouracil Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Fluorouracil + 10-hydroxycamptothecin DCWEM7J Fluorouracil Malignant melanoma (Cell Line: A375) [4]
Fluorouracil + 10-hydroxycamptothecin DCED75J Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [4]
Fluorouracil + 10-hydroxycamptothecin DC06DKX Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [4]
Fluorouracil + 10-hydroxycamptothecin DCC9M3U Fluorouracil Malignant melanoma (Cell Line: UACC62) [4]
Fluorouracil + 10-hydroxycamptothecin DCM5FI4 Fluorouracil Mesothelioma (Cell Line: MSTO) [4]
Fluorouracil + 10-hydroxycamptothecin DCY7K0S Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [4]
Fluorouracil + 10-hydroxycamptothecin DC8WTOF Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Fluorouracil + 10-hydroxycamptothecin DC83KN7 Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Fluorouracil + 10-hydroxycamptothecin DCHADAA Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [4]
Fluorouracil + 10-hydroxycamptothecin DCABMER Fluorouracil Prostate carcinoma (Cell Line: VCAP) [4]
Fomepizole + 10-hydroxycamptothecin DCSA0TW Fomepizole Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Fulvestrant + 10-hydroxycamptothecin DC9WV0O Fulvestrant Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Fulvestrant + 10-hydroxycamptothecin DC2TWJK Fulvestrant Renal cell carcinoma (Cell Line: SN12C) [2]
Gefitinib + 10-hydroxycamptothecin DCDYPSE Gefitinib Adenocarcinoma (Cell Line: NCIH23) [2]
Gefitinib + 10-hydroxycamptothecin DC753LI Gefitinib Adenocarcinoma (Cell Line: HT29) [2]
Gefitinib + 10-hydroxycamptothecin DCVAFF2 Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Gefitinib + 10-hydroxycamptothecin DCJX5VN Gefitinib Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Gefitinib + 10-hydroxycamptothecin DCUZS45 Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Gefitinib + 10-hydroxycamptothecin DCFLDOU Gefitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Gefitinib + 10-hydroxycamptothecin DCIJNGE Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Gefitinib + 10-hydroxycamptothecin DCF8CFQ Gefitinib Glioma (Cell Line: SF-295) [2]
Gefitinib + 10-hydroxycamptothecin DCB0UE3 Gefitinib Glioma (Cell Line: SF-539) [2]
Gefitinib + 10-hydroxycamptothecin DC5093V Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Gefitinib + 10-hydroxycamptothecin DC9M17P Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Gefitinib + 10-hydroxycamptothecin DCF7SUR Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [2]
Gefitinib + 10-hydroxycamptothecin DC4CPHQ Gefitinib Melanoma (Cell Line: SK-MEL-2) [2]
Gefitinib + 10-hydroxycamptothecin DC4SS0O Gefitinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Gefitinib + 10-hydroxycamptothecin DCF11XV Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Gefitinib + 10-hydroxycamptothecin DCFZC9V Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Gefitinib + 10-hydroxycamptothecin DCYZHMV Gefitinib Carcinoma (Cell Line: MCF7) [3]
GS4071 + 10-hydroxycamptothecin DCAB1O2 GS4071 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
GSK525762 + 10-hydroxycamptothecin DCTGQ2O GSK525762 Carcinoma (Cell Line: MDAMB436) [3]
GSK525762 + 10-hydroxycamptothecin DCHK4D4 GSK525762 Adenocarcinoma (Cell Line: CAOV3) [4]
GSK525762 + 10-hydroxycamptothecin DCRYY97 GSK525762 Adenocarcinoma (Cell Line: OVCAR3) [4]
GSK525762 + 10-hydroxycamptothecin DCXDNSX GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
GSK525762 + 10-hydroxycamptothecin DC1PPVT GSK525762 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Hepzato + 10-hydroxycamptothecin DCY2MDL Hepzato Adenocarcinoma (Cell Line: HCC-2998) [4]
Hyodeoxycholic acid + 10-hydroxycamptothecin DCQYFOB Hyodeoxycholic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Idarubicin + 10-hydroxycamptothecin DCEIS06 Idarubicin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Idarubicin + 10-hydroxycamptothecin DCTDZRI Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [4]
Idarubicin + 10-hydroxycamptothecin DCJYYQA Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [4]
Idarubicin + 10-hydroxycamptothecin DCPSQTW Idarubicin Amelanotic melanoma (Cell Line: A2058) [4]
Idarubicin + 10-hydroxycamptothecin DCTSC9P Idarubicin Malignant melanoma (Cell Line: RPMI7951) [4]
Idarubicin + 10-hydroxycamptothecin DC3FGF0 Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Imatinib + 10-hydroxycamptothecin DC5ADTT Imatinib Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Imatinib + 10-hydroxycamptothecin DCU1J2Q Imatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Indazole derivative 5 + 10-hydroxycamptothecin DCUIF1P Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Indazole derivative 5 + 10-hydroxycamptothecin DCY7MXH Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Indazole derivative 5 + 10-hydroxycamptothecin DCTIQOB Indazole derivative 5 Astrocytoma (Cell Line: SNB-19) [2]
Indazole derivative 5 + 10-hydroxycamptothecin DCP6MUO Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Indazole derivative 5 + 10-hydroxycamptothecin DCQJB7F Indazole derivative 5 Adenocarcinoma (Cell Line: SW-620) [4]
Indazole derivative 5 + 10-hydroxycamptothecin DC0UAJZ Indazole derivative 5 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Indazole derivative 5 + 10-hydroxycamptothecin DCH4LEY Indazole derivative 5 Lung adenocarcinoma (Cell Line: NCI-H522) [4]
IT-141 + 10-hydroxycamptothecin DC3ST7W IT-141 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
JNK-IN-8 + 10-hydroxycamptothecin DCFFPUL JNK-IN-8 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + 10-hydroxycamptothecin DCDUOLY JNK-IN-8 Papillary renal cell carcinoma (Cell Line: ACHN) [2]
JNK-IN-8 + 10-hydroxycamptothecin DCB7XO8 JNK-IN-8 Adenocarcinoma (Cell Line: NCIH23) [4]
JNK-IN-8 + 10-hydroxycamptothecin DCXCIIZ JNK-IN-8 Amelanotic melanoma (Cell Line: M14) [4]
Lacosamide + 10-hydroxycamptothecin DC25PFQ Lacosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Lapatinib + 10-hydroxycamptothecin DCMK5L0 Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + 10-hydroxycamptothecin DCMVN2J Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + 10-hydroxycamptothecin DCYY5QV Lapatinib Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + 10-hydroxycamptothecin DCABNXY Lapatinib Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + 10-hydroxycamptothecin DCMB29X Lapatinib Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + 10-hydroxycamptothecin DCVV5JB Lapatinib Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + 10-hydroxycamptothecin DC8PSQC Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + 10-hydroxycamptothecin DC3G8OR Lapatinib Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + 10-hydroxycamptothecin DCWB95I Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + 10-hydroxycamptothecin DCEEF8Q Lapatinib Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + 10-hydroxycamptothecin DCK2ECZ Lapatinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + 10-hydroxycamptothecin DCICV7F Lapatinib Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + 10-hydroxycamptothecin DCBPWTC Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + 10-hydroxycamptothecin DC8UDM5 Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + 10-hydroxycamptothecin DCKUWWT Lapatinib Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + 10-hydroxycamptothecin DCTXZ1H Lapatinib Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + 10-hydroxycamptothecin DCMTCJY Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + 10-hydroxycamptothecin DC5RSD2 Lapatinib Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + 10-hydroxycamptothecin DC0FXKV Lapatinib Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + 10-hydroxycamptothecin DC5OR6V Lapatinib Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + 10-hydroxycamptothecin DCMYLNI Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + 10-hydroxycamptothecin DC58MBB Lapatinib Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + 10-hydroxycamptothecin DCPANJV Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + 10-hydroxycamptothecin DC9W1EE Lapatinib Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + 10-hydroxycamptothecin DC40JSC Lapatinib Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + 10-hydroxycamptothecin DC2CGAW Lapatinib Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + 10-hydroxycamptothecin DCL4VEE Lapatinib Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + 10-hydroxycamptothecin DCJCCX4 Lapatinib Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + 10-hydroxycamptothecin DC6LWIP Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + 10-hydroxycamptothecin DCICFPV Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + 10-hydroxycamptothecin DC78PYN Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + 10-hydroxycamptothecin DCSCOXK Lapatinib Prostate carcinoma (Cell Line: VCAP) [4]
LIAROZOLE + 10-hydroxycamptothecin DCAS1HV LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
LIAROZOLE + 10-hydroxycamptothecin DCOBU1V LIAROZOLE Anaplastic large cell lymphoma (Cell Line: SR) [2]
LIAROZOLE + 10-hydroxycamptothecin DCS0S2U LIAROZOLE Astrocytoma (Cell Line: SNB-19) [2]
LIAROZOLE + 10-hydroxycamptothecin DCB6QVS LIAROZOLE Glioma (Cell Line: SF-539) [2]
LIAROZOLE + 10-hydroxycamptothecin DCYV29T LIAROZOLE Papillary renal cell carcinoma (Cell Line: ACHN) [2]
LIAROZOLE + 10-hydroxycamptothecin DC5K6U4 LIAROZOLE Amelanotic melanoma (Cell Line: M14) [4]
LIAROZOLE + 10-hydroxycamptothecin DCZ2FHY LIAROZOLE Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Maprotiline + 10-hydroxycamptothecin DCQBIPI Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Mechlorethamine + 10-hydroxycamptothecin DCKHV4K Mechlorethamine Adenocarcinoma (Cell Line: DU-145) [4]
Mefloquine + 10-hydroxycamptothecin DC2FO6C Mefloquine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Methylene blue + 10-hydroxycamptothecin DCEJSE8 Methylene blue Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Methylergonovine + 10-hydroxycamptothecin DC309C1 Methylergonovine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
MK-1775 + 10-hydroxycamptothecin DCYAV9W MK-1775 Adenocarcinoma (Cell Line: CAOV3) [2]
MK-1775 + 10-hydroxycamptothecin DCKJVC3 MK-1775 Adenocarcinoma (Cell Line: A427) [2]
MK-1775 + 10-hydroxycamptothecin DCJU6CE MK-1775 Adenocarcinoma (Cell Line: NCIH1650) [2]
MK-1775 + 10-hydroxycamptothecin DCSFCWT MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [2]
MK-1775 + 10-hydroxycamptothecin DCT3STD MK-1775 Adenocarcinoma (Cell Line: NCIH23) [2]
MK-1775 + 10-hydroxycamptothecin DCTACFW MK-1775 Adenocarcinoma (Cell Line: NCIH520) [2]
MK-1775 + 10-hydroxycamptothecin DCFHGLW MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [2]
MK-1775 + 10-hydroxycamptothecin DCE8N91 MK-1775 Adenocarcinoma (Cell Line: DLD1) [2]
MK-1775 + 10-hydroxycamptothecin DCLYDCN MK-1775 Adenocarcinoma (Cell Line: HCT116) [2]
MK-1775 + 10-hydroxycamptothecin DCNBFSS MK-1775 Adenocarcinoma (Cell Line: HT29) [2]
MK-1775 + 10-hydroxycamptothecin DCMYNM0 MK-1775 Adenocarcinoma (Cell Line: SW-620) [2]
MK-1775 + 10-hydroxycamptothecin DCRBVT9 MK-1775 Amelanotic melanoma (Cell Line: A2058) [2]
MK-1775 + 10-hydroxycamptothecin DC7JN0B MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-1775 + 10-hydroxycamptothecin DCBUPKM MK-1775 Germ cell tumour (Cell Line: PA1) [2]
MK-1775 + 10-hydroxycamptothecin DCXOCQE MK-1775 Malignant melanoma (Cell Line: A375) [2]
MK-1775 + 10-hydroxycamptothecin DCOX20A MK-1775 Malignant melanoma (Cell Line: HT144) [2]
MK-1775 + 10-hydroxycamptothecin DCUFHTV MK-1775 Malignant melanoma (Cell Line: RPMI7951) [2]
MK-1775 + 10-hydroxycamptothecin DCL12RU MK-1775 Malignant melanoma (Cell Line: SKMEL30) [2]
MK-1775 + 10-hydroxycamptothecin DC7WTA4 MK-1775 Malignant melanoma (Cell Line: UACC62) [2]
MK-1775 + 10-hydroxycamptothecin DC7F29S MK-1775 Mesothelioma (Cell Line: MSTO) [2]
MK-1775 + 10-hydroxycamptothecin DCRANYM MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [2]
MK-1775 + 10-hydroxycamptothecin DCIPYX0 MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
MK-1775 + 10-hydroxycamptothecin DCE7JZD MK-1775 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
MK-1775 + 10-hydroxycamptothecin DCS1873 MK-1775 Prostate carcinoma (Cell Line: LNCAP) [2]
MK-1775 + 10-hydroxycamptothecin DCW7VLR MK-1775 Prostate carcinoma (Cell Line: VCAP) [2]
MK-1775 + 10-hydroxycamptothecin DCAIH7B MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-1775 + 10-hydroxycamptothecin DCQITCE MK-1775 Breast carcinoma (Cell Line: ZR751) [3]
MK-1775 + 10-hydroxycamptothecin DCR4NH7 MK-1775 Breast carcinoma (Cell Line: KPL1) [3]
MK-1775 + 10-hydroxycamptothecin DCEVLLZ MK-1775 Breast carcinoma (Cell Line: OCUBM) [3]
MK-1775 + 10-hydroxycamptothecin DCD287V MK-1775 Carcinoma (Cell Line: OV90) [3]
MK-1775 + 10-hydroxycamptothecin DCLK4KW MK-1775 Carcinoma (Cell Line: EFM192B) [3]
MK-1775 + 10-hydroxycamptothecin DCY5C8B MK-1775 Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-1775 + 10-hydroxycamptothecin DC0R11T MK-1775 Colon carcinoma (Cell Line: RKO) [3]
MK-1775 + 10-hydroxycamptothecin DCZOGE0 MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-2206 + 10-hydroxycamptothecin DCLZL4L MK-2206 Adenocarcinoma (Cell Line: A427) [2]
MK-2206 + 10-hydroxycamptothecin DCTFUP0 MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [2]
MK-2206 + 10-hydroxycamptothecin DCJ20OX MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [2]
MK-2206 + 10-hydroxycamptothecin DC4SOSF MK-2206 Adenocarcinoma (Cell Line: DLD1) [2]
MK-2206 + 10-hydroxycamptothecin DCVCGNT MK-2206 Adenocarcinoma (Cell Line: HT29) [2]
MK-2206 + 10-hydroxycamptothecin DCADA1Y MK-2206 Amelanotic melanoma (Cell Line: A2058) [2]
MK-2206 + 10-hydroxycamptothecin DCF234O MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-2206 + 10-hydroxycamptothecin DCTM5N0 MK-2206 Germ cell tumour (Cell Line: PA1) [2]
MK-2206 + 10-hydroxycamptothecin DCQWUA1 MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
MK-2206 + 10-hydroxycamptothecin DCSYJK0 MK-2206 Malignant melanoma (Cell Line: HT144) [2]
MK-2206 + 10-hydroxycamptothecin DCHGIVM MK-2206 Malignant melanoma (Cell Line: SKMEL30) [2]
MK-2206 + 10-hydroxycamptothecin DCN64MP MK-2206 Malignant melanoma (Cell Line: UACC62) [2]
MK-2206 + 10-hydroxycamptothecin DC3MOV6 MK-2206 Malignant melanoma (Cell Line: RPMI7951) [2]
MK-2206 + 10-hydroxycamptothecin DC2A41P MK-2206 Mesothelioma (Cell Line: MSTO) [2]
MK-2206 + 10-hydroxycamptothecin DCCDRUT MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [2]
MK-2206 + 10-hydroxycamptothecin DCX8YE0 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
MK-2206 + 10-hydroxycamptothecin DC7UJYZ MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
MK-2206 + 10-hydroxycamptothecin DCF9UUB MK-2206 Prostate carcinoma (Cell Line: LNCAP) [2]
MK-2206 + 10-hydroxycamptothecin DCU8W8Q MK-2206 Prostate carcinoma (Cell Line: VCAP) [2]
MK-2206 + 10-hydroxycamptothecin DCLCL34 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-2206 + 10-hydroxycamptothecin DC57IE4 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-2206 + 10-hydroxycamptothecin DC3HCW9 MK-2206 Breast carcinoma (Cell Line: KPL1) [3]
MK-2206 + 10-hydroxycamptothecin DCN4DCA MK-2206 Breast carcinoma (Cell Line: OCUBM) [3]
MK-2206 + 10-hydroxycamptothecin DCLVP7G MK-2206 Carcinoma (Cell Line: OV90) [3]
MK-2206 + 10-hydroxycamptothecin DCTQRCO MK-2206 Carcinoma (Cell Line: EFM192B) [3]
MK-2206 + 10-hydroxycamptothecin DCP5BJ3 MK-2206 Carcinoma (Cell Line: MDAMB436) [3]
MK-2206 + 10-hydroxycamptothecin DCM2FII MK-2206 Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-2206 + 10-hydroxycamptothecin DCLEQFW MK-2206 Colon carcinoma (Cell Line: RKO) [3]
MK-2206 + 10-hydroxycamptothecin DCGI4CV MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-4827 + 10-hydroxycamptothecin DC3QOO0 MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-4827 + 10-hydroxycamptothecin DCSAYP9 MK-4827 Breast carcinoma (Cell Line: KPL1) [3]
MK-4827 + 10-hydroxycamptothecin DCL7X4H MK-4827 Breast carcinoma (Cell Line: OCUBM) [3]
MK-4827 + 10-hydroxycamptothecin DCSYC51 MK-4827 Carcinoma (Cell Line: EFM192B) [3]
MK-4827 + 10-hydroxycamptothecin DCQEWFZ MK-4827 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-4827 + 10-hydroxycamptothecin DCZ9C5V MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-4827 + 10-hydroxycamptothecin DCGTHLV MK-4827 Adenocarcinoma (Cell Line: A427) [4]
MK-4827 + 10-hydroxycamptothecin DCDYXZW MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-4827 + 10-hydroxycamptothecin DCFT0CP MK-4827 Adenocarcinoma (Cell Line: HT29) [4]
MK-4827 + 10-hydroxycamptothecin DCDVMON MK-4827 Amelanotic melanoma (Cell Line: A2058) [4]
MK-4827 + 10-hydroxycamptothecin DCN7Q9T MK-4827 Germ cell tumour (Cell Line: PA1) [4]
MK-4827 + 10-hydroxycamptothecin DCLCK79 MK-4827 Malignant melanoma (Cell Line: HT144) [4]
MK-4827 + 10-hydroxycamptothecin DCYXQT0 MK-4827 Malignant melanoma (Cell Line: UACC62) [4]
MK-4827 + 10-hydroxycamptothecin DCY0W6B MK-4827 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-4827 + 10-hydroxycamptothecin DCB8GMJ MK-4827 Mesothelioma (Cell Line: MSTO) [4]
MK-4827 + 10-hydroxycamptothecin DC36PMW MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-4827 + 10-hydroxycamptothecin DCMT4I4 MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-4827 + 10-hydroxycamptothecin DC979RX MK-4827 Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + 10-hydroxycamptothecin DCX3LUQ MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + 10-hydroxycamptothecin DCGRFMF MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + 10-hydroxycamptothecin DCK8NJU MK-5108 Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + 10-hydroxycamptothecin DCVHLJC MK-5108 Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + 10-hydroxycamptothecin DCDSOC2 MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + 10-hydroxycamptothecin DCJE7HQ MK-5108 Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + 10-hydroxycamptothecin DCTU3AB MK-5108 Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + 10-hydroxycamptothecin DCNWGYJ MK-5108 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + 10-hydroxycamptothecin DC87YTV MK-5108 Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + 10-hydroxycamptothecin DCHH7K5 MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + 10-hydroxycamptothecin DC24S20 MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + 10-hydroxycamptothecin DCT62Z8 MK-5108 Prostate carcinoma (Cell Line: VCAP) [4]
Mycophenolic acid + 10-hydroxycamptothecin DCZ7PDE Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Niclosamide + 10-hydroxycamptothecin DCU26H6 Niclosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Nitrosoglutathione + 10-hydroxycamptothecin DCQUK5M Nitrosoglutathione Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Paromomycin + 10-hydroxycamptothecin DC1NQD7 Paromomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
PD-0325901 + 10-hydroxycamptothecin DC3M3GN PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
PD-0325901 + 10-hydroxycamptothecin DCULI4N PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
PD-0325901 + 10-hydroxycamptothecin DCLZJYD PD-0325901 Breast carcinoma (Cell Line: OCUBM) [3]
PD-0325901 + 10-hydroxycamptothecin DCCBSPR PD-0325901 Carcinoma (Cell Line: OV90) [3]
PD-0325901 + 10-hydroxycamptothecin DC0IGVP PD-0325901 Carcinoma (Cell Line: EFM192B) [3]
PD-0325901 + 10-hydroxycamptothecin DCOULPS PD-0325901 Carcinoma (Cell Line: MDAMB436) [3]
PD-0325901 + 10-hydroxycamptothecin DCQ6IVY PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [3]
PD-0325901 + 10-hydroxycamptothecin DCWP4UV PD-0325901 Colon carcinoma (Cell Line: RKO) [3]
PD-0325901 + 10-hydroxycamptothecin DCORORD PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [3]
PD-0325901 + 10-hydroxycamptothecin DCSW617 PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [4]
PD-0325901 + 10-hydroxycamptothecin DCGQGLV PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [4]
PD-0325901 + 10-hydroxycamptothecin DC512IH PD-0325901 Adenocarcinoma (Cell Line: A427) [4]
PD-0325901 + 10-hydroxycamptothecin DCRQTO0 PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [4]
PD-0325901 + 10-hydroxycamptothecin DC1Z2PU PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [4]
PD-0325901 + 10-hydroxycamptothecin DCRC4QZ PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [4]
PD-0325901 + 10-hydroxycamptothecin DC0JW1U PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [4]
PD-0325901 + 10-hydroxycamptothecin DC3NEQQ PD-0325901 Adenocarcinoma (Cell Line: DLD1) [4]
PD-0325901 + 10-hydroxycamptothecin DCUY83H PD-0325901 Adenocarcinoma (Cell Line: HT29) [4]
PD-0325901 + 10-hydroxycamptothecin DCW661X PD-0325901 Adenocarcinoma (Cell Line: SW-620) [4]
PD-0325901 + 10-hydroxycamptothecin DCWYFIN PD-0325901 Amelanotic melanoma (Cell Line: A2058) [4]
PD-0325901 + 10-hydroxycamptothecin DCMQVWX PD-0325901 Germ cell tumour (Cell Line: PA1) [4]
PD-0325901 + 10-hydroxycamptothecin DCPE1GD PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
PD-0325901 + 10-hydroxycamptothecin DCJUER8 PD-0325901 Malignant melanoma (Cell Line: A375) [4]
PD-0325901 + 10-hydroxycamptothecin DCBCZNG PD-0325901 Malignant melanoma (Cell Line: HT144) [4]
PD-0325901 + 10-hydroxycamptothecin DCC3175 PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [4]
PD-0325901 + 10-hydroxycamptothecin DC11Z6W PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [4]
PD-0325901 + 10-hydroxycamptothecin DCVARCZ PD-0325901 Malignant melanoma (Cell Line: UACC62) [4]
PD-0325901 + 10-hydroxycamptothecin DCUW7E7 PD-0325901 Mesothelioma (Cell Line: MSTO) [4]
PD-0325901 + 10-hydroxycamptothecin DCFKJTR PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [4]
PD-0325901 + 10-hydroxycamptothecin DCSJ851 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PD-0325901 + 10-hydroxycamptothecin DCIS3V1 PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
PD-0325901 + 10-hydroxycamptothecin DCQAGLU PD-0325901 Prostate carcinoma (Cell Line: VCAP) [4]
PF-02545920 + 10-hydroxycamptothecin DCVLW6D PF-02545920 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Pinacidil + 10-hydroxycamptothecin DCEU750 Pinacidil Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCM7O46 PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC9NTB5 PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC8I16C PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC460P9 PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCOHWWV PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCWDIJD PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCLOSRF PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: LOVO) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCD0CQT PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCEAAH5 PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCL9ADU PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [3]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCS6DEY PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC4NRL0 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCPV3OI PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCF0IWR PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCZ2UJD PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCAUY3D PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC1ME6K PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCBW055 PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCR8CWM PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC72659 PMID28460551-Compound-2 Malignant melanoma (Cell Line: HT144) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCEK702 PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCHFQ77 PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC4AMUG PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC6QI84 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC7UYVF PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCAC6GK PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DC1N3C2 PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCV5L6E PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [4]
PMID28460551-Compound-2 + 10-hydroxycamptothecin DCZKO2V PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [4]
Quinine + 10-hydroxycamptothecin DC2K90I Quinine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raloxifene + 10-hydroxycamptothecin DC1L666 Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Romidepsin + 10-hydroxycamptothecin DCP3FGD Romidepsin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Romidepsin + 10-hydroxycamptothecin DC54XWQ Romidepsin Astrocytoma (Cell Line: U251) [2]
Romidepsin + 10-hydroxycamptothecin DCOVAD6 Romidepsin Astrocytoma (Cell Line: SNB-19) [2]
Romidepsin + 10-hydroxycamptothecin DCRD6IL Romidepsin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Romidepsin + 10-hydroxycamptothecin DCOJBUO Romidepsin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
RTB101 + 10-hydroxycamptothecin DCEI2EO RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
RTB101 + 10-hydroxycamptothecin DC70T79 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
RTB101 + 10-hydroxycamptothecin DCO7IGG RTB101 Breast carcinoma (Cell Line: KPL1) [3]
RTB101 + 10-hydroxycamptothecin DCAQ2G2 RTB101 Breast carcinoma (Cell Line: OCUBM) [3]
RTB101 + 10-hydroxycamptothecin DCANIEV RTB101 Carcinoma (Cell Line: OV90) [3]
RTB101 + 10-hydroxycamptothecin DCLV1F4 RTB101 Carcinoma (Cell Line: EFM192B) [3]
RTB101 + 10-hydroxycamptothecin DC1OJR8 RTB101 Carcinoma (Cell Line: MDAMB436) [3]
RTB101 + 10-hydroxycamptothecin DCQF1SQ RTB101 Colon adenocarcinoma (Cell Line: LOVO) [3]
RTB101 + 10-hydroxycamptothecin DCIUOPX RTB101 Colon carcinoma (Cell Line: RKO) [3]
RTB101 + 10-hydroxycamptothecin DCVV2VP RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [3]
RTB101 + 10-hydroxycamptothecin DCK4H65 RTB101 Adenocarcinoma (Cell Line: CAOV3) [4]
RTB101 + 10-hydroxycamptothecin DCDER3M RTB101 Adenocarcinoma (Cell Line: A427) [4]
RTB101 + 10-hydroxycamptothecin DCU89D9 RTB101 Adenocarcinoma (Cell Line: NCIH1650) [4]
RTB101 + 10-hydroxycamptothecin DCI5ZDI RTB101 Adenocarcinoma (Cell Line: NCIH2122) [4]
RTB101 + 10-hydroxycamptothecin DC61SB2 RTB101 Adenocarcinoma (Cell Line: NCIH23) [4]
RTB101 + 10-hydroxycamptothecin DCNBLJJ RTB101 Adenocarcinoma (Cell Line: NCIH520) [4]
RTB101 + 10-hydroxycamptothecin DCJS2P9 RTB101 Adenocarcinoma (Cell Line: COLO320DM) [4]
RTB101 + 10-hydroxycamptothecin DC195ZG RTB101 Adenocarcinoma (Cell Line: DLD1) [4]
RTB101 + 10-hydroxycamptothecin DC5FL23 RTB101 Adenocarcinoma (Cell Line: HCT116) [4]
RTB101 + 10-hydroxycamptothecin DC1TSGF RTB101 Adenocarcinoma (Cell Line: HT29) [4]
RTB101 + 10-hydroxycamptothecin DC25U1I RTB101 Adenocarcinoma (Cell Line: SW-620) [4]
RTB101 + 10-hydroxycamptothecin DC0QG2Q RTB101 Germ cell tumour (Cell Line: PA1) [4]
RTB101 + 10-hydroxycamptothecin DCA4PKC RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
RTB101 + 10-hydroxycamptothecin DC73RMG RTB101 Malignant melanoma (Cell Line: A375) [4]
RTB101 + 10-hydroxycamptothecin DCGQTR9 RTB101 Malignant melanoma (Cell Line: HT144) [4]
RTB101 + 10-hydroxycamptothecin DCBB4AQ RTB101 Malignant melanoma (Cell Line: SKMEL30) [4]
RTB101 + 10-hydroxycamptothecin DC4VG6Z RTB101 Malignant melanoma (Cell Line: UACC62) [4]
RTB101 + 10-hydroxycamptothecin DCVDE1Y RTB101 Malignant melanoma (Cell Line: RPMI7951) [4]
RTB101 + 10-hydroxycamptothecin DC78ZRE RTB101 Mesothelioma (Cell Line: MSTO) [4]
RTB101 + 10-hydroxycamptothecin DCBLW49 RTB101 Non small cell carcinoma (Cell Line: SKMES1) [4]
RTB101 + 10-hydroxycamptothecin DCUHBEJ RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
RTB101 + 10-hydroxycamptothecin DCJGGBO RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
RTB101 + 10-hydroxycamptothecin DCQJMLK RTB101 Prostate carcinoma (Cell Line: LNCAP) [4]
RTB101 + 10-hydroxycamptothecin DCHJCX9 RTB101 Prostate carcinoma (Cell Line: VCAP) [4]
Ruxolitinib + 10-hydroxycamptothecin DCV4SPO Ruxolitinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Ruxolitinib + 10-hydroxycamptothecin DCXZK8U Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Ruxolitinib + 10-hydroxycamptothecin DCOAA3J Ruxolitinib Adenocarcinoma (Cell Line: SW-620) [4]
Ruxolitinib + 10-hydroxycamptothecin DCO2Z54 Ruxolitinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
SCH 727965 + 10-hydroxycamptothecin DCIKU5O SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
SCH 727965 + 10-hydroxycamptothecin DCS7S2U SCH 727965 Breast carcinoma (Cell Line: KPL1) [3]
SCH 727965 + 10-hydroxycamptothecin DCL7Y0G SCH 727965 Breast carcinoma (Cell Line: OCUBM) [3]
SCH 727965 + 10-hydroxycamptothecin DC5ECRN SCH 727965 Carcinoma (Cell Line: EFM192B) [3]
SCH 727965 + 10-hydroxycamptothecin DCQB9JS SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [3]
SCH 727965 + 10-hydroxycamptothecin DC1GXW1 SCH 727965 Colon carcinoma (Cell Line: RKO) [3]
SCH 727965 + 10-hydroxycamptothecin DCSEVUH SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [4]
SCH 727965 + 10-hydroxycamptothecin DCPB73B SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [4]
SCH 727965 + 10-hydroxycamptothecin DCDZPOW SCH 727965 Adenocarcinoma (Cell Line: A427) [4]
SCH 727965 + 10-hydroxycamptothecin DCPGCMQ SCH 727965 Adenocarcinoma (Cell Line: NCIH1650) [4]
SCH 727965 + 10-hydroxycamptothecin DCKD99J SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [4]
SCH 727965 + 10-hydroxycamptothecin DCL5PPA SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [4]
SCH 727965 + 10-hydroxycamptothecin DCGV8E7 SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [4]
SCH 727965 + 10-hydroxycamptothecin DC3P7GW SCH 727965 Adenocarcinoma (Cell Line: DLD1) [4]
SCH 727965 + 10-hydroxycamptothecin DCRJ5AZ SCH 727965 Adenocarcinoma (Cell Line: HCT116) [4]
SCH 727965 + 10-hydroxycamptothecin DCX2HO7 SCH 727965 Adenocarcinoma (Cell Line: HT29) [4]
SCH 727965 + 10-hydroxycamptothecin DCLEAIF SCH 727965 Adenocarcinoma (Cell Line: SW-620) [4]
SCH 727965 + 10-hydroxycamptothecin DCYL316 SCH 727965 Amelanotic melanoma (Cell Line: A2058) [4]
SCH 727965 + 10-hydroxycamptothecin DC4S44I SCH 727965 Germ cell tumour (Cell Line: PA1) [4]
SCH 727965 + 10-hydroxycamptothecin DC7OTQE SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
SCH 727965 + 10-hydroxycamptothecin DC92FJ5 SCH 727965 Malignant melanoma (Cell Line: A375) [4]
SCH 727965 + 10-hydroxycamptothecin DCH1QF2 SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [4]
SCH 727965 + 10-hydroxycamptothecin DCNH31A SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [4]
SCH 727965 + 10-hydroxycamptothecin DCJVISE SCH 727965 Malignant melanoma (Cell Line: UACC62) [4]
SCH 727965 + 10-hydroxycamptothecin DCAIQR2 SCH 727965 Mesothelioma (Cell Line: MSTO) [4]
SCH 727965 + 10-hydroxycamptothecin DCRAIJC SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [4]
SCH 727965 + 10-hydroxycamptothecin DCCZBWU SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
SCH 727965 + 10-hydroxycamptothecin DC5BUZQ SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
SCH 727965 + 10-hydroxycamptothecin DCK8T8X SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [4]
SCH 727965 + 10-hydroxycamptothecin DCJ3JPL SCH 727965 Prostate carcinoma (Cell Line: VCAP) [4]
Sitagliptin + 10-hydroxycamptothecin DCCL7JT Sitagliptin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
SNX-2112 + 10-hydroxycamptothecin DC93ESL SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
SNX-2112 + 10-hydroxycamptothecin DCYF5KP SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
SNX-2112 + 10-hydroxycamptothecin DCBJ5ZR SNX-2112 Carcinoma (Cell Line: OV90) [3]
SNX-2112 + 10-hydroxycamptothecin DCEL6FF SNX-2112 Carcinoma (Cell Line: EFM192B) [3]
SNX-2112 + 10-hydroxycamptothecin DCFTFMH SNX-2112 Carcinoma (Cell Line: MDAMB436) [3]
SNX-2112 + 10-hydroxycamptothecin DC8B6X5 SNX-2112 Colon carcinoma (Cell Line: RKO) [3]
SNX-2112 + 10-hydroxycamptothecin DCP11S1 SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [3]
SNX-2112 + 10-hydroxycamptothecin DC1IIBI SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [4]
SNX-2112 + 10-hydroxycamptothecin DCANRJR SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [4]
SNX-2112 + 10-hydroxycamptothecin DCXP2JZ SNX-2112 Adenocarcinoma (Cell Line: A427) [4]
SNX-2112 + 10-hydroxycamptothecin DCD7R11 SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [4]
SNX-2112 + 10-hydroxycamptothecin DC3Q9HX SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [4]
SNX-2112 + 10-hydroxycamptothecin DC9HM8I SNX-2112 Adenocarcinoma (Cell Line: DLD1) [4]
SNX-2112 + 10-hydroxycamptothecin DC4NSF8 SNX-2112 Adenocarcinoma (Cell Line: HCT116) [4]
SNX-2112 + 10-hydroxycamptothecin DC7SB24 SNX-2112 Adenocarcinoma (Cell Line: SW-620) [4]
SNX-2112 + 10-hydroxycamptothecin DCO90PJ SNX-2112 Amelanotic melanoma (Cell Line: A2058) [4]
SNX-2112 + 10-hydroxycamptothecin DC3IBVQ SNX-2112 Germ cell tumour (Cell Line: PA1) [4]
SNX-2112 + 10-hydroxycamptothecin DCMWXGG SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
SNX-2112 + 10-hydroxycamptothecin DC5OEZQ SNX-2112 Malignant melanoma (Cell Line: A375) [4]
SNX-2112 + 10-hydroxycamptothecin DCGHUWR SNX-2112 Malignant melanoma (Cell Line: HT144) [4]
SNX-2112 + 10-hydroxycamptothecin DCFUW4Z SNX-2112 Malignant melanoma (Cell Line: RPMI7951) [4]
SNX-2112 + 10-hydroxycamptothecin DC6EM8H SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [4]
SNX-2112 + 10-hydroxycamptothecin DCIG8QC SNX-2112 Malignant melanoma (Cell Line: UACC62) [4]
SNX-2112 + 10-hydroxycamptothecin DCED0WS SNX-2112 Mesothelioma (Cell Line: MSTO) [4]
SNX-2112 + 10-hydroxycamptothecin DCR3QZ4 SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [4]
SNX-2112 + 10-hydroxycamptothecin DCQCD32 SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
SNX-2112 + 10-hydroxycamptothecin DCHMH0N SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
SNX-2112 + 10-hydroxycamptothecin DCSUVTN SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [4]
SNX-2112 + 10-hydroxycamptothecin DC7X0HL SNX-2112 Prostate carcinoma (Cell Line: VCAP) [4]
SY-1425 + 10-hydroxycamptothecin DCOCTM7 SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
SY-1425 + 10-hydroxycamptothecin DCXM5N3 SY-1425 Astrocytoma (Cell Line: U251) [2]
Taxol + 10-hydroxycamptothecin DCP1XFT Taxol Glioma (Cell Line: SF-539) [2]
Teriflunomide + 10-hydroxycamptothecin DCPN6D0 Teriflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Testosterone cypionate + 10-hydroxycamptothecin DCMWYKO Testosterone cypionate Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Thioguanine + 10-hydroxycamptothecin DCMMX0S Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Thioguanine + 10-hydroxycamptothecin DCZOF2P Thioguanine Glioma (Cell Line: SF-295) [2]
Thioguanine + 10-hydroxycamptothecin DCHVUET Thioguanine Adenocarcinoma (Cell Line: DU-145) [4]
Thioguanine + 10-hydroxycamptothecin DC1O0NU Thioguanine Adenocarcinoma (Cell Line: HT29) [4]
Tiagabine + 10-hydroxycamptothecin DCJ3K9E Tiagabine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Topotecan + 10-hydroxycamptothecin DCHXXJQ Topotecan Adenocarcinoma (Cell Line: A549) [4]
Topotecan + 10-hydroxycamptothecin DCBKJ88 Topotecan Melanoma (Cell Line: MALME-3M) [4]
Topotecan + 10-hydroxycamptothecin DCBN5IP Topotecan Melanoma (Cell Line: UACC-257) [4]
Topotecan + 10-hydroxycamptothecin DCLMILN Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Topotecan + 10-hydroxycamptothecin DCLNW4U Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Topotecan + 10-hydroxycamptothecin DCKY0LC Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Topotecan + 10-hydroxycamptothecin DCE2M5F Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Trifluridine + 10-hydroxycamptothecin DC3XMGX Trifluridine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Trifluridine + 10-hydroxycamptothecin DC9OA40 Trifluridine Adenocarcinoma (Cell Line: HT29) [4]
Trifluridine + 10-hydroxycamptothecin DCVF2XT Trifluridine Amelanotic melanoma (Cell Line: M14) [4]
Uracil mustard + 10-hydroxycamptothecin DC9E5ES Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Vandetanib + 10-hydroxycamptothecin DCSS1WG Vandetanib Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + 10-hydroxycamptothecin DC7UA8P Vandetanib Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + 10-hydroxycamptothecin DC8C8K1 Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + 10-hydroxycamptothecin DC1HNBI Vandetanib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vemurafenib + 10-hydroxycamptothecin DCDBSN5 Vemurafenib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vemurafenib + 10-hydroxycamptothecin DCAV4PF Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vemurafenib + 10-hydroxycamptothecin DCU7Y52 Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vemurafenib + 10-hydroxycamptothecin DCCTHFD Vemurafenib Malignant melanoma (Cell Line: UACC62) [4]
Vemurafenib + 10-hydroxycamptothecin DCJH50E Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [4]
Vemurafenib + 10-hydroxycamptothecin DCJI54G Vemurafenib Melanoma (Cell Line: MALME-3M) [4]
Vincristine + 10-hydroxycamptothecin DCGE2HJ Vincristine Amelanotic melanoma (Cell Line: M14) [2]
Vincristine + 10-hydroxycamptothecin DCQRUSU Vincristine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Vismodegib + 10-hydroxycamptothecin DCK9FWS Vismodegib Carcinoma (Cell Line: MCF7) [3]
Vismodegib + 10-hydroxycamptothecin DCXAUYL Vismodegib Adenocarcinoma (Cell Line: DU-145) [4]
Vismodegib + 10-hydroxycamptothecin DCKNDYW Vismodegib Adenocarcinoma (Cell Line: NCIH23) [4]
Vismodegib + 10-hydroxycamptothecin DC027DB Vismodegib Adenocarcinoma (Cell Line: HCT116) [4]
Vismodegib + 10-hydroxycamptothecin DC8MK7P Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vismodegib + 10-hydroxycamptothecin DCM28YV Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vismodegib + 10-hydroxycamptothecin DCV95W0 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vismodegib + 10-hydroxycamptothecin DCILKWW Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vismodegib + 10-hydroxycamptothecin DC6TR3K Vismodegib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vismodegib + 10-hydroxycamptothecin DCXO82B Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vismodegib + 10-hydroxycamptothecin DCMRW3C Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vismodegib + 10-hydroxycamptothecin DCSVXAE Vismodegib Prostate carcinoma (Cell Line: PC-3) [4]
WAY-100635 + 10-hydroxycamptothecin DC3J8S1 WAY-100635 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 770 DrugCom(s)

References

1 Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.